Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-4106 and mRNA-4200 in Advanced Solid Tumors
NCT06880549Phase 1Recruiting
- Sponsor
- Moderna Inc
- Start
- Mar 2025
- Primary completion
- Aug 2027
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of mRNA-4106 and mRNA-4200 in solid tumor (advanced stage) (2 arms), sponsored by Moderna Inc. Primary endpoints: Number of Participants With Dose Limiting Toxicities at 42 days and Number of Participants With Treatment Emergent Adverse Events, Serious Adverse Events and Adverse Events of Special Interest. Started Mar 2025; status: recruiting.
02
Drugs
mRNA-4106mRNA-4200
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06880549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06880549.